Last edition
News about "Arrowhead Pharmaceuticals "
Arrowhead Pharmaceuticals Wins Australia TGA Approval for REDEMPLO
Arrowhead Pharmaceuticals receives TGA approval for REDEMPLO (plozasiran) in Australia, the first treatment for Familial Chylomicronemia Syndrome (FCS), backed by phase 3 data showing significant triglyceride reduction and lower pancreatitis risk.
Arrowhead Pharmaceuticals | 01/05/2026 | By News Bureau | 125
Arrowhead Pharmaceuticals Reports Long-Term Efficacy, Safety Data for Plozasiran
Arrowhead Pharmaceuticals reports long-term phase 2b data showing plozasiran reduces triglycerides by 83 percent in sHTG patients, with no pancreatitis events and sustained improvements in lipid markers and safety.
Arrowhead Pharmaceuticals | 30/03/2026 | By News Bureau | 167
Arrowhead and Novartis Sign Global License and Collaboration Deal
Novartis secures exclusive global rights to Arrowhead’s ARO-SNCA therapy for Parkinson’s and related disorders, with Arrowhead receiving USD 200 million upfront.
Arrowhead Pharmaceuticals | 05/09/2025 | By Dineshwori | 244
Arrowhead Pharmaceuticals Expands its New Patient-Centric Resources for FCS Patients
This new phase introduces a dedicated educational website, and the Spotlight on FCS white paper, which provides essential resources and support for those affected by Familial Chylomicronemia Syndrome (FCS).
Arrowhead Pharmaceuticals | 03/03/2025 | By Aishwarya | 254
Arrowhead Pharmaceuticals Secures FDA Breakthrough Therapy Designation for Plozasiran
Arrowhead intends to submit a New Drug Application to the FDA by year-end 2024 and plans to seek regulatory approval with additional global regulatory authorities thereafter.
Arrowhead Pharmaceuticals | 13/09/2024 | By Aishwarya | 525
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy